All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Epidermal growth factor receptor (EGFR) is a transmembrane protein that is activated by binding of its specific ligands. Epidermal growth factor receptor isoform (EGFRvA) has higher tumor-promoting capacity than EGFR. Moreover, EGFRvA is more stable than EGFR because of its decreased binding to E3 ubiquitin ligase c-CbI. EGFRvA as a drug target is associated with lung cancer, colon cancer, anal cancer, glioblastoma and epithelian tumors of the head and neck.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
CAR-MZ187 | Anti-EGFRvA (2D3) h(CD3ζ) CAR, pCDCAR1 | Human | 2D3 | Mouse | scFv-CD3ζ | Lentiviral | T cell | ||
CAR-MZ188 | Anti-EGFRvA (2D3) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 2D3 | Mouse | scFv-CD28-CD3ζ | Lentiviral | T cell | ||
CAR-MZ189 | Anti-EGFRvA (2D3) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 2D3 | Mouse | scFv-41BB-CD3ζ | Lentiviral | T cell | ||
CAR-MZ190 | Anti-EGFRvA (2D3) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | 2D3 | Mouse | scFv-CD28-41BB-CD3ζ | Lentiviral | T cell |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION